{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"44.4","value":"713"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"This outcome measure presents maximum measured concentration of Volasertib 200 mg in plasma (Cmax).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"The patients received Volasertib 200 mg administered by Intravenous Infusion (IV) over 60 minutes on Day 1 and Day 15 of 28-day and Azacitidine 75 mg/m\\^2 administered by subcutaneous injection on days 1-7 of 28 day treatment cycle.","id":"OG000","title":"Volasertib 200 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Treated Set (TS): This patient set included all patients who were dispensed study medication and were documented to have taken at least one dose of either Volasertib or Azacitidine.","reportingStatus":"POSTED","timeFrame":"-0.05 hours before drug administration and 0:30 (hours:minutes), 1:00, 1:30, 2:00, 3:00, 4:00, 24:30, 48:30, 96:30, 144:30 and 335:55 after drug administration.","title":"Maximum Measured Concentration of the Volasertib 200 mg in Plasma (Cmax)","type":"SECONDARY","unitOfMeasure":"ng/mL"}